Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
11.2 USD | +1.31% | -0.18% | +29.10% |
04-19 | Lake Street Starts Cellebrite DI With Buy Rating, $13 Price Target | MT |
04-01 | BofA Securities Adjusts Cellebrite DI Price Target to $13 From $12, Maintains Buy Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+29.10% | 2.27B | |
+10.20% | 3,082B | |
+8.06% | 84.92B | |
+4.66% | 78.23B | |
-14.19% | 54.06B | |
-23.28% | 46.79B | |
+21.64% | 45.87B | |
+22.36% | 42.68B | |
+57.79% | 37.28B | |
-10.44% | 24.89B |
- Stock Market
- Equities
- CLBT Stock
- News Cellebrite DI Ltd.
- Cellebrite DI's Q4 Adjusted Earnings, Revenue Gain; Sets Revenue Outlook for Q1, 2024